Palvella Therapeutics, Inc.
PVLA
$50.13
-$3.29-6.16%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 240.61% | 206.32% | 91.56% | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 247.68% | 122.35% | 19.66% | -- | -- |
| Operating Income | -247.68% | -122.35% | -19.66% | -- | -- |
| Income Before Tax | -358.04% | -200.94% | -167.33% | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -358.04% | -200.94% | -167.33% | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -358.04% | -200.94% | -167.33% | -- | -- |
| EBIT | -247.68% | -122.35% | -19.66% | -- | -- |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 9.01% | -623.51% | -723.21% | -- | -- |
| Normalized Basic EPS | 32.47% | -356.04% | -1,200.92% | -- | -- |
| EPS Diluted | 9.01% | -620.09% | -725.40% | -- | -- |
| Normalized Diluted EPS | 32.47% | -344.43% | -1,264.94% | -- | -- |
| Average Basic Shares Outstanding | 159.00% | 55.92% | -11.40% | -- | -- |
| Average Diluted Shares Outstanding | 159.00% | 54.97% | -11.85% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |